

Comparison of MetAP2 Homologues (mouse = SEQ ID NO:13; rat = SEQ ID NO:17;
human = SEQ ID NO:12; yeast = SEQ ID NO:14)

1	15	16	30	31	45	46	60	61	75	76	90
mouse	MAGVEQAASFGGHLN	GDLDPDDREECTSST	AEAAKKRRKKKK	KGAVSAVQQELDKES	GALVDEVAKQLERQA	LEEKERDDDDG	90				
rat	MAGVEEASSFGGHLN	RDLDPDDREECTSST	AEAAKKRRKKKK	KGAVSAGQQELDKES	GTSVDEVAKQLERQA	LEEKEKDDDDG	90				
human	MAGVEEVAASGSHLN	GDLDPDDREEGAAS	AEAAKKRRKKKK	KGPSAAGEQEPDKES	GASVDEVARQLERSA	LEKKEKDDDDG	90				
yeast	-----	-----	-----	-----	-----	-----	38				
	105	106	120	121	135	136	150	151	165	166	180
mouse	DADGATGKKKKKKK	KRGPKVQTDPPSVPI	CDLYPNGVFPKGQEC	EYPPTQDGRTAAWRT	TSEKKALDQASEEI	WPDFREAAEAHRQVR	180				
rat	DGDGAAGKKKKKKK	KRGPRVQTDPPSVPI	CDLYPNGVFPKGQEC	EYPPTQDGRTAAWRT	TSEKKALDQASEEI	WPDFREAAEAHRQVR	180				
human	DGDGATGKKKKKKK	KRGPKVQTDPPSVPI	CDLYPNGVFPKGQEC	EYPPTQDGRTAAWRT	TSEKKALDQASEEI	WPDFREAAEAHRQVR	180				
yeast	ESKKKKKKKKKKKK	N-----	VKKI	ELLFPDGKYPEGAWM	DYHDFNLQRTTDEE	SRYLKRDLEA--EH	WPDFREAAEAHRQVR	116			
	181	195	196	210	211	225	226	240	241	255	256
mouse	KVMSWIKPGMTMIE	ICEKLEDCSRKLIKE	NGLNAG-----	LA	FPTGCSLNNCAAHYT	PNAGDTTVLQYDDIC	KIDFGTHISGRIIDC	263			
rat	KVMSWIKPGMTMIE	ICEKLEDCSRKLIKE	NGLNAG-----	LA	FPTGCSLNNCAAHYT	PNAGDTTVLQYDDIC	KIDFGTHISGRIIDC	263			
human	KVMSWIKPGMTMIE	ICEKLEDCSRKLIKE	NGLNAG-----	LA	FPTGCSLNNCAAHYT	PNAGDTTVLQYDDIC	KIDFGTHISGRIIDC	263			
yeast	RAIKDRIVPGMKLMD	IADMIENTTRKYTGA	ENLLAMEDPKSQGIG	FPTGLSLNHCAAHT	PNAGDKTVLKVEDVM	KVDYGVQVNGNIIDS	206				
	271	285	286	300	301	315	316	330	331	345	346
mouse	AFTVTFNPKYDILLT	AVKDATNTGIKCAGI	DVRLCDVGEAIOEVM	ESYEVEIDGTYQVK	PIRNLNHSGIGPYRI	HAGKTVPIVKGGEAT	353				
rat	AFTVTFNPKYDILLK	AVKDATNTGIKCAGI	DVRLCDVGEAIOEVM	ESYEVEIDGTYQVK	PIRNLNHSGIGPYRI	HAGKTVPIVKGGEAT	353				
human	AFTVTFNPKYDILLK	AVKDATNTGIKCAGI	DVRLCDVGEAIOEVM	ESYEVEIDGTYQVK	PIRNLNHSGIGPYRI	HAGKTVPIVKGGEAT	353				
yeast	AFTVSFDPQYDNLIA	AVKDATYTGKEAGI	DVRLTDIGEAIQEV	ESYEVEINGETQVK	PCRNLCGHSIAPYRI	HGGKSVPIVKNKGT	296				
	361	375	376	390	391	405	406	420	421	435	436
mouse	RMEEGEVAIETFGS	TGKGVVHDDMECSHY	MKNFVGVHVPRLPR	TKHLLNVINENFGTL	AFCRRWLDRLGESKY	LMALKNLCDLGIVDP	443				
rat	RMEEGEVAIETFGS	TGKGVVHDDMECSHY	MKNFVGVHVPRLPR	TKHLLNVINENFGTL	AFCRRWLDRLGESKY	LMALKNLCDLGIVDP	443				
human	RMEEGEVAIETFGS	TGKGVVHDDMECSHY	MKNFVGVHVPRLPR	TKHLLNVINENFGTL	AFCRRWLDRLGESKY	LMALKNLCDLGIVDP	443				
yeast	KMEEGEHAETFGS	TGRGYVTAGGEVSHY	ARSAEDHQVMPILDS	AKNLLKTIDRNFGLT	PCRRYLDRLGQEKY	LFALNNLVRHGLVQD	386				
	451	465	466	480							
mouse	YPPLCDIKGSYTAQF	EHTILLRPTCKEVVS	RGDDY--	478							
rat	YPPLCDIKGSYTAQF	EHTILCAQPVKKLSA	EEMTIKT	480							
human	YPPLCDIKGSYTAQF	EHTILLRPTCKEVVS	RGDDY--	478							
yeast	YPPLNDIPGSYTAQF	EHTILLHAHKKEVVS	KGDDY--	421							

Figure 1




Figure 2



A. Glucose

B. Galactose




Figure 3






Figure 4




A. Glucose

B. Galactose





H174A-MetAP2 requires N-terminal residues 2-57 for inhibition of *map1 Δ* growth under the GAL1 promoter.

Figure 5



The steady state levels of each MetAP2 construct are comparable. Immunoblot comparison of HA-MetAP2 wt, HA-MetAP2 H174A, and MetAP2 $\Delta 2-57$ H174A steady state levels in *map1Δ*.

Figure 6



Overexpression of H174A-MetAP2 under the GPD promoter does not inhibit the growth of map2Δ

Figure 7




FIGURE 8




FIGURE 9





Figure 10

202010" E2TEH660

A



B




Figure 11